# Lilly

> Lilly is a global pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Our products are sold in approximately 125 countries. We unite caring with discovery to create medicines that make life better for people around the world.

Lilly publishes its public content at https://lilly.relayto.com/. Every link below goes to a Markdown version of the page; drop the `.md` suffix for the interactive page, or request any page URL with `Accept: text/markdown`.

## When to use this site

- To find, read and cite what Lilly has published here, including: Bamlanivimab for HCP | USA.
- To answer questions about Lilly from its own documents rather than third-party summaries.
- Read the Markdown versions linked below: they carry the page text, which the interactive viewer renders with JavaScript.
- The full list of page URLs is in the sitemap: https://lilly.relayto.com/sitemap.xml

## Tools for AI agents

- [Content server (MCP)](https://lilly.relayto.com/mcp/server-card): public and read-only, no sign-in, at `https://lilly.relayto.com/mcp` (Streamable HTTP); tools `search_content`, `list_hubs`, `get_content`. The link is its server card.
- [Authentication for agents](https://lilly.relayto.com/auth.md): reading this site needs no credentials.
- [Agent skill](https://lilly.relayto.com/.well-known/agent-skills/index.json): how to find, read and cite this site.
- [RELAYTO MCP server](https://mcp.relayto.com/mcp/server-card): Lilly publishes this site on RELAYTO; its editors manage the content through RELAYTO's MCP server at `https://mcp.relayto.com/mcp` after signing in with a RELAYTO account (OAuth). RELAYTO operates it; it is not needed to read the site. The link is its server card.
- [relayto-mcp on npm](https://www.npmjs.com/package/relayto-mcp): `npx -y relayto-mcp --site lilly.relayto.com` runs this site's read-only MCP server (`https://lilly.relayto.com/mcp`) for stdio MCP clients, no sign-in
- [relayto on npm](https://www.npmjs.com/package/relayto): SDK and command line, e.g. `npx relayto search "report" --site lilly.relayto.com` or `npx relayto hubs --site lilly.relayto.com`
- [com.relayto/site-content](https://registry.modelcontextprotocol.io/v0.1/servers/com.relayto%2Fsite-content/versions/latest): MCP Registry entry of every RELAYTO site's content server, here `https://lilly.relayto.com/mcp`
- [com.relayto/mcp](https://registry.modelcontextprotocol.io/v0.1/servers/com.relayto%2Fmcp/versions/latest): MCP Registry entry of RELAYTO's MCP server for signed-in workspace members
- [relayto/relayto-mcp on GitHub](https://github.com/relayto/relayto-mcp): source and docs of these tools

## Hubs

- [Bamlanivimab for HCP | USA](https://lilly.relayto.com/hub/bamlanivimab-for-hcp-usa-5fbcdac642edf.md)

## Content

- [Antibody Playbook](https://lilly.relayto.com/e/antibody-playbook-9h9jyzt6qiuk1.md): Bamlanivimab Antibody Playbook | November 2020
- [FAQ](https://lilly.relayto.com/e/faq-5fbced1bc1c6e.md): FAQ and Resources
- [Access](https://lilly.relayto.com/e/access-5fbcdac12b417.md): Allocation of Bamlanivimab in U.S.
- [Dosage](https://lilly.relayto.com/e/dosage-5fbce7308ed45.md): Dosage and Administration Overview
- [Bamlanivimab](https://lilly.relayto.com/e/bamlanivimab-5fbcce1307d1a.md): Emergency Use Authorization (EUA) for the Treatment of COVID-19
- [Patient Guide](https://lilly.relayto.com/e/patient-guide-hjdwbmev69bc1.md): What You Need to Know about Bamlanivimab | 7 Pages
- [HCP-Patient Counseling Guide](https://lilly.relayto.com/e/hcp-patient-counseling-guide-edi5fxcu5p75h.md): What to Expect during a COVID-19 Neutralizing Antibody Treatment Infusion | 8 Pages
- [NEJM - Neutralizing Antibody LY-COV555](https://lilly.relayto.com/e/nejm-neutralizing-antibody-ly-cov555-7vmtnd709cgo2.md): SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19 | 9 Pages
- [Fact Sheet for Health Care Providers](https://lilly.relayto.com/e/fact-sheet-for-health-care-providers-8fxsuuca9ytwa.md): Fact Sheet | 23 Pages
- [FDA Letter of Authorization](https://lilly.relayto.com/e/fda-letter-of-authorization-0vi9pyv5qbp5y.md): FDA Letter of Authorization | 35 Pages
- [Fact Sheet for Patients, Parents & Caregivers (English)](https://lilly.relayto.com/e/fact-sheet-for-patients-parents-caregivers-english-bmifsyx175r5h.md): Emergency Use Authorization of Bamlanivimab for COVID-19 | 3 Pages
- [Fact Sheet for Patients, Parents & Caregivers (Spanish)](https://lilly.relayto.com/e/fact-sheet-for-patients-parents-caregivers-spanish-2roeak8eqzvgj.md): Autorización de uso de emergencia de bamlanivimab para la enfermedad por COVID-19 | 3 Pages
- [Neutralizing Antibody Infographic](https://lilly.relayto.com/e/neutralizing-antibody-infographic-j37bwphd6tr1r.md): Allocation Flow in the U.S. | 1 Page

## API

- [Lilly API documentation](https://lilly.relayto.com/developers.md): JSON API to search and read this site's pages, hubs and documents; no API key
- [API index for agents](https://lilly.relayto.com/developers/llms.txt): the endpoints, one link each
- [API sandbox index](https://lilly.relayto.com/docs/sandbox/llms.txt): the sandbox and its sample data, for testing an integration
- [OpenAPI 3.1 description](https://lilly.relayto.com/openapi.json)
